期刊
MEDIATORS OF INFLAMMATION
卷 2010, 期 -, 页码 -出版社
HINDAWI LTD
DOI: 10.1155/2010/143026
关键词
-
资金
- Eleventh Five-year Plan for AIDS and viral hepatitis, prevention and treatment of infectious diseases and other major science and technology [2008ZX10002-004]
- Ministry of Health Clinical Branches [20073531]
- National Natural Science Foundation of China [30771912, 30972610]
- Jilin Province Science and Technology Agency [200705128]
Adefovir dipivoxil treatment has significantly improved the outcome of chronic hepatitis B virus (HBV) infection. However, it remains largely unknown how immune system responds to the treatment. Chronic HBV patients were treated with adefovir dipivoxil and examined for serum HBV DNA loads, cytokines, and T helper (Th1) and 2 (Th2) cytokine producing T cells during 104 weeks of the treatment. Th1/Th2 cytokines producing T cells were significantly lower in chronic HBV patients as compared to normal individuals. Adefovir dipivoxil treatment led to the increase of Th1/Th2 cytokines producing T cells and serum cytokine levels in association with the decline of HVB DNA load. In contrast, Th1/Th2 cytokines producing T cells remained lower in one patient detected with adefovir dipivoxil resistant HBV A181T/V mutation. This study has established inverse correlation of the increase of Th1/Th2 immunity and the decline of HBV DNA load in chronic HBV patients during adefovir dipivoxil treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据